KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) Profit After Tax: 2014-2024

Historic Profit After Tax for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$366.3 million.

  • CRISPR Therapeutics AG's Profit After Tax fell 23.85% to -$106.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$488.3 million, marking a year-over-year decrease of 103.80%. This contributed to the annual value of -$366.3 million for FY2024, which is 138.43% down from last year.
  • CRISPR Therapeutics AG's Profit After Tax amounted to -$366.3 million in FY2024, which was down 138.43% from -$153.6 million recorded in FY2023.
  • CRISPR Therapeutics AG's Profit After Tax's 5-year high stood at $377.7 million during FY2021, with a 5-year trough of -$650.2 million in FY2022.
  • In the last 3 years, CRISPR Therapeutics AG's Profit After Tax had a median value of -$366.3 million in 2024 and averaged -$390.0 million.
  • In the last 5 years, CRISPR Therapeutics AG's Profit After Tax plummeted by 621.80% in 2020 and then surged by 208.25% in 2021.
  • Yearly analysis of 5 years shows CRISPR Therapeutics AG's Profit After Tax stood at -$348.9 million in 2020, then surged by 208.25% to $377.7 million in 2021, then plummeted by 272.16% to -$650.2 million in 2022, then surged by 76.37% to -$153.6 million in 2023, then crashed by 138.43% to -$366.3 million in 2024.